Uristat Urinary Pain Relief Tablets
Nonprescription temporary pain relief from the makers of Monistat products. Uristat contains phenazopyridine HCI, the No.1 doctor recommended medication used to treat pain or discomfort experienced while urinating.
- Fast temporary relief of pain, burning, urgency and frequency of urination
- Easy-to-swallow tablet form
- Brought to you by the makers of Monistat the No.1 recommendation of doctors and the #1 choice of women for OTC vaginal yeast infection treatments.
Please Read Item Label and Packaging for Recent Product Information.
- Adults and children 12 years of age and over: take 2 tablets, 3 times daily with a full glass of water, with or after meals as needed.
- Children under 12 years of age: consult a doctor
- Do not use for more than 2 days (12 tablets) without consulting a doctor.
Do not exceed recommended dosage.
Ask a doctor before you use if you have:
- Do not take if you have previously exhibited hypersensitivity to phenazopyridine HCI or if you have kidney trouble. Remember that advanced age is associated with declining kidney function. Discontinue therapy if you experience a yellowish tinge of the skin or eyes. This may indicate accumulation due to impaired kidney or liver function.
- As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using the product. If your symptoms persist, are severe, or you experience fever, chills, back pain or bloody urine see your doctor promptly. You may have a serious condition that requires different treatment.
- Phenazopyridine HCI may cause gastrointestinal upset in some people. Take with or after meals to reduce gastric upset and discontinue use if symptoms occur.
- This product may stain soft contact lenses.
- Keep this and all drugs out of reach of children and do not administer to children under the age of 12 unless directed by a physician.
- In case of accidental overdose, seek professional assistance or contact a poison control center immediately.
- Carcinogenesis: Long-term administration of phenazopyridine HCI has induced neoplasia in rats (large intestine) and mice (liver). Although no association between phenazopyridine HCI and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted.
Shipping Weight : 0.20 lb